Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcrisantaspase with Fludarabine and Cytarabine in R/R Leukemia
NCT04526795Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegcrisantaspase in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), T-cell prolymphocytic leukemia (T-PLL) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 5 weeks. Started Apr 2021; status: terminated.
02
Drugs
pegcrisantaspase
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)T-cell prolymphocytic leukemia (T-PLL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04526795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526795.